BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Supreme Court Sends Pfizer Inc. (PFE)-Cipla Ltd. Case Back to Patent Office


11/29/2012 7:19:52 AM

In a landmark ruling, the Supreme Court, has sent back a case involving crucial renal cancer drug, Sunitinib (sold as Sutent by Pfizer) to the patent authority, according to a lawyer involved in the case. This implies that the patent authority will re-examine the case, while the domestic company, Cipla is expected to argue against granting of the patent to Pfizer, all over again. At the same time, the court has ruled in favour of Cipla, by lifting an injunction against it, which may pave the way for the launch of a generic version of the drug. Pfizer was granted a patent for kidney cancer drug Sutent in India in 2007. Significantly, Cipla filed a post-grant application and won the case in September this year, with the Patent Office rejecting the claims made by Pfizer over the drug, on grounds that the invention claimed in patent (Sutent ) did not involve an inventive step. Following this, Pfizer appealed in the Delhi high court which granted an injunction restraining Cipla from launching the drug. Last month, Cipla filed an appeal in the Supreme Court against the high court order.

Read at India Times
Read at PharmaBiz

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->